Vyjuvek was approved in 2023, initially for patients at least six months of age, and could only be applied by healthcare professionals.

Investigators have used base editing to create a treatment for multisystemic smooth muscle dysfunction syndrome, which has ...

The firm's commercialization push is fueled by $35.6 million from a recent Series C financing and a $15.5 million ...

Funded through a $17 million NIH grant, the program will try six strategies to combat HIV and advance the most promising.

The agency said it will accept data from single-arm trials in its newly released Rare Disease Evidence Principles, but ...

NEW YORK – Lantern Pharma has a clearer vision of how it wants to study LP-184, a DNA-damaging small molecule, in pediatric ...

Autonomous AI tools have great potential in supporting precision medicine, but developers are still figuring out how to deploy them in patient care.

Phase II/III data showed that advanced gastric cancer patients on anbenitamab and chemotherapy fared better than those on standard therapy.

Some feel the guidance may encourage consistent follow-up of overall survival after accelerated approvals, but others remain focused on speeding new drugs to patients.

The company announced results from a Phase Ib trial of the drug as a first-line monotherapy for EGFR PACC-mutated NSCLC.

Cambridge, Massachusetts-based Amylyx announced pricing of an underwritten public offering of 17,500,000 shares of its common stock at a public offering price of $10 per share. The firm has also ...

The German firm is weighing how best to leverage genetic testing in developing the antidepressant, which Sanofi had ...